Building Better
Medicines with AI
Model Medicines is Innovating at the Intersection of Data Science, Biology and Drug Development
We are focused on discovering drugs with best-in-class potential against rigorous target product profiles, not merely creating thousands of hits that never reach the clinic or pharmacy.
Through GALILEO™, we’ve discovered 192 compounds for 26 targets, validated with multiple world class academic and corporate laboratories. Our programs have been validated with the leading academic and corporate research laboratories in the world.
Advancing a best-in-class and first-in-class, pan-antiviral candidate
MDL-001’s antiviral activity was discovered by Model Medicines’ GALILEO™ Platform and developed in collaboration with world-renowned researchers at Scripps Research and the Icahn School of Medicine at Mount Sinai. The drug is being developed as a therapeutic with broad antiviral activity with a lead indication in SARS-CoV-2/COVID-19.
We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19.
— David “Davey” Smith, MD, MAS, FACP, FIDSA
We recognize that no one business can revolutionize the way medicines are discovered and developed on their own. We want to leverage our technology and expertise in partnership with the world’s leading researchers and scientists.
We’re an AI-Driven,
Human Health Company
Located in the techbio hub of La Jolla, CA, our goal is to elevate human health through a "success by design" approach to drug discovery, knowing that true innovation happens at the intersection of data, biology and drug development.
We're building advanced AI models that can understand complex biology and chemistry to create better medicines tailored to patients' needs.
We're hiring at the intersection of Data Science, Biology and Drug Development
Partnerships
We put strategic partnerships at the heart of our approach. We focus on providing AI-driven drug discovery services to biopharma companies.
Investors
Model Medicines is backed by top investors with deep industry knowledge and a successful history of forming some of the world’s leading techbio companies.
